1. Home
  2. SPRO vs ACU Comparison

SPRO vs ACU Comparison

Compare SPRO & ACU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • ACU
  • Stock Information
  • Founded
  • SPRO 2013
  • ACU 1867
  • Country
  • SPRO United States
  • ACU United States
  • Employees
  • SPRO N/A
  • ACU N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • ACU Industrial Machinery/Components
  • Sector
  • SPRO Health Care
  • ACU Consumer Discretionary
  • Exchange
  • SPRO Nasdaq
  • ACU Nasdaq
  • Market Cap
  • SPRO 128.9M
  • ACU 145.9M
  • IPO Year
  • SPRO 2017
  • ACU N/A
  • Fundamental
  • Price
  • SPRO $2.33
  • ACU $38.39
  • Analyst Decision
  • SPRO Buy
  • ACU
  • Analyst Count
  • SPRO 4
  • ACU 0
  • Target Price
  • SPRO $5.00
  • ACU N/A
  • AVG Volume (30 Days)
  • SPRO 1.2M
  • ACU 11.0K
  • Earning Date
  • SPRO 11-13-2025
  • ACU 10-21-2025
  • Dividend Yield
  • SPRO N/A
  • ACU 1.66%
  • EPS Growth
  • SPRO N/A
  • ACU N/A
  • EPS
  • SPRO N/A
  • ACU 2.45
  • Revenue
  • SPRO $48,576,000.00
  • ACU $194,960,991.00
  • Revenue This Year
  • SPRO N/A
  • ACU $2.85
  • Revenue Next Year
  • SPRO N/A
  • ACU $4.16
  • P/E Ratio
  • SPRO N/A
  • ACU $15.75
  • Revenue Growth
  • SPRO N/A
  • ACU 2.35
  • 52 Week Low
  • SPRO $0.51
  • ACU $34.35
  • 52 Week High
  • SPRO $3.22
  • ACU $45.42
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 56.08
  • ACU 39.94
  • Support Level
  • SPRO $2.16
  • ACU $37.55
  • Resistance Level
  • SPRO $2.42
  • ACU $39.35
  • Average True Range (ATR)
  • SPRO 0.12
  • ACU 0.89
  • MACD
  • SPRO -0.00
  • ACU 0.11
  • Stochastic Oscillator
  • SPRO 46.85
  • ACU 43.52

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About ACU Acme United Corporation.

Acme United Corp is a supplier of first aid and medical products and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its principal products sold across all segments are first aid kits and medical products, scissors, shears, knives, rulers, pencil sharpeners, and sharpening tools. The Company sells its products to mass market and e-commerce retailers, industrial distributors, wholesale, contract, and retail stationery distributors, office supply superstores, sporting goods stores, and hardware chains. The Company's reportable business segments consist of the United States, Canada, and Europe, out of which the majority of the company's revenue is derived from the United States.

Share on Social Networks: